RESUMO
Many risk factors lead to hypohepatia and hepatic failure,causing people suffering from end-stage liver disease.The conventional treatment for end-stage liver disease is not good enough.Orthotopic liver transplantation is effective.However,the high cost,lack of liver source,immune rejection and other factors limit the large-scale clinical application.Thus,cell therapy is a good option.Studies on common cell sources for the treatment of liver disease and the induction of hepatocytes by embryonic stem cells or pluripotent stem cells have made progress.With the development of stem cell technology,cell transplantation has become a new option,which brings hope to people with end-stage liver diseasetransplantation has become a new option.It brings hope to people with endstage liver disease.
RESUMO
Embryonic stem cells (ESCs) is one of the best cell types for regenerative medicine. It is derived from inner cell mass of the blastocyst stage and characterized by self-renewal and pluripotency, which are regulated by kinds of signal molecules, such as the Wnt/β-catenin signaling pathway. β-catenin is a multifunctional protein and plays a key role in Wnt/β-catenin signaling pathway. β-catenin involves self-renewal of ESCs and promotes the differentiation of ESCs into three primary germ layers in space and time. Elucidating the mechanisms of β-catenin in regulating the self-renewal and pluripotency of ESCs will pave the way to use it in research and application.